The purpose of this observational study is to describe the actual conditions of prescription of micafungin in antifungal prophylaxis in French haematological and onco-haematological units. The efficacy and the safety outcomes will be described.
Study Type
OBSERVATIONAL
Enrollment
150
intravenous
Site
Angers, France
Site
Angers, France
Site
Béziers, France
Breakthrough incidence of Invasive Fungal Infection (IFI), defined according to the revised EORTC/MSG criteria, during prophylaxis use of micafungin
EORTC/MSG : European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group
Time frame: Up to 3 months
Odds ratio and 95% CI for each identified risk factors
Time frame: Up to 3 months
Incidence of IFI, defined according to the revised EORTC/MSG criteria
Time frame: Up to 3 months
Characteristics of patients treated with micafungin
Time frame: Day 0 (start of prophylaxis)
Conditions of use of micafungin
dose and administration pattern, temporary interruptions and treatment duration, oral treatment take-over
Time frame: Up to 3 months
Description of adverse events (AE) and serious adverse events (SAE)
Time frame: Up to 3 months
Characteristics of units
participating physicians (age, status, specialty), type of institution, location , type of unit, size of unit
Time frame: Day 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site
Bordeaux, France
Site
Brest, France
Site
Clermont-Ferrand, France
Site
Lille, France
Site
Limoges, France
Site
Marseille, France
Site
Marseille, France
...and 7 more locations